Related Experiment Video

Updated: Aug 24, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Long-term oral carvedilol in chronic heart failure

Andrea Di Lenarda1, Gastone Sabbadini, Michele Moretti

  • 1University of Trieste, Department of Cardiology, Ospedale di Cattinara, Strada Di Fiume 447, 34100 Trieste, Italy. dilenar@univ.ts.it

Expert Opinion on Pharmacotherapy
|May 28, 2004
PubMed

Insights

Carvedilol may be the preferred beta-blocker for chronic heart failure (CHF) patients. It offers comprehensive antiadrenergic activity and has shown greater survival benefits compared to other agents.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers like carvedilol, metoprolol succinate, and bisoprolol are recommended for chronic heart failure (CHF).
  • Carvedilol's unique profile suggests potential superiority due to comprehensive antiadrenergic activity and ancillary properties.

Purpose of the Study:

  • To evaluate the potential superiority of carvedilol over metoprolol and bisoprolol in managing CHF.
  • To highlight carvedilol's effectiveness and safety in a broad CHF patient population.

Main Methods:

  • Review of existing clinical trials and pharmacological data.
  • Comparison of carvedilol's efficacy and safety profile against metoprolol and bisoprolol.

Main Results:

  • Carvedilol has demonstrated effectiveness and safety in a wider CHF patient range.
  • A recent trial showed significantly greater survival benefits with carvedilol versus metoprolol tartrate.

Conclusions:

  • Carvedilol may be the preferred beta-blocking agent for treating patients with CHF.
  • Its comprehensive pharmacological profile contributes to superior outcomes in certain CHF populations.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...